Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma

NCT02645981 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

668

Enrollment

INDUSTRY

Sponsor class

Conditions

HCC

Interventions

DRUG: Donafenib
DRUG: Sorafenib

Sponsor

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Collaborators

[object Object]